Empreses emergents
2014
IMIDOMICS SLINFORMACIONS CRÍTIQUES PER AL TRACTAMENT DE PACIENTS AMB MALALTIES INFLAMATÒRIES IMMUNITATIVES IMID biobanc de pacients i dipòsit de dades clíniques de la més alta qualitat
Adreça
Carrer de Baldiri Reixac 4-8, 08028 Barcelona, Espanya
Xarxes socials

Dades financeres

DataInversorsQuantitatEtapa 
Jul 202115.000.000 €Early VC

Resum financer

Encara no s'han registrat ingressos

Propietat CERCA

Àrees d'estat i deeptech

Estat de l'empresa i àrees de tecnologia profunda de l'empresa

Estat de l'empresa

Estat de l'empresa

Àrea DeepTech

Àrea DeepTech

Informació sobre la spin-off

Descripció de l'empresa

Our Vision: to drive changes to traditional drug discovery and treatment strategies by employing state-of-the-art methods and technologies to deeply understand patients and their underlying conditions

Our Mission: to partner with Pharma, Health companies, Payers, Big Data and Physicians to develop precision medicine diagnostics and new therapeutics that optimize treatment of IMID patients

Descripció del producte

IMID PATIENTS
Immune-mediated inflammatory disease (IMID) is a concept to describe a group of chronic disorders characterized by the activation of multiple immune and inflammatory pathways. Although each IMID targets different tissues and organs, they all share common clinical features and molecular mechanisms. Their etiology is unknown although genetic and environmental factors are crucial determinants of susceptibility. The estimated prevalence of IMIDs is 7–10% in the general population. IMIDs are associated with a high socio-economic impact and are among the main causes of morbidity, disability, and mortality in developed countries
IMID BIOBANK
IMIDomics has access to the IMID-Biobank, a dynamic, high-quality ISO certified biobank ensures the availability of high-quality biological products to be analyzed using cutting-edge technologies
MULTIOMICS
At IMIDomics we are convinced that only through the integration of data from multiple omic approaches, together with reliable clinical data, that precision medicine will be delivered to IMID patients
PORTAL
IMIDomics portal provides seamless access the biological insights generated through the use of different omic technologies on IMID patients

Dades temporals

KTT temporal

29-07-2025 Formation Bio ha llicenciat els drets mundials del primer anticòs monoclonal (mAb) anti-CD226 d'IMIDomics.   Enllaç a les notícies